Navigation Links
EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
Date:9/22/2008

AMSTERDAM, September 22 /PRNewswire/ -- Kiadis Pharma announced today that its lead product ATIR(TM) has been granted orphan drug designation (ODD) by the European Medicines Agency (EMEA) for the prevention of acute Graft versus Host Disease (GvHD) following an allogeneic bone marrow transplantation.

"Following the orphan drug designation granted by the FDA for our lead product ATIR(TM), this is another important milestone in the development of ATIR(TM) as a novel approach which may enable a safe and potentially life-saving mismatched bone marrow transplantation as a treatment option for end-stage blood cancer patients" says Dr. Manja Bouman, Chief Executive Officer of Kiadis Pharma.

The EMEA's orphan drug designation is reserved for new therapies being developed to treat life-threatening or chronically debilitating diseases or conditions that are relatively rare in the European Union and for which no satisfactory therapy is available. The orphan drug designation provides for incentives to support research and development, exemption from user fees and a ten-year period of market exclusivity in the European Union after product approval.

For the complete press release please go to: http://www.kiadis.com/news

About Kiadis Pharma

Kiadis Pharma is an oncology focused pharmaceutical development company with three products in different phases of clinical development. The company develops products that offer novel treatment options for terminally ill cancer patients and address significant unmet medical needs. The key focus indication for Kiadis Pharma is limitations and complications of bone marrow transplantation procedures performed in blood cancer patients. Kiadis Pharma is headquartered in Amsterdam, The Netherlands with facilities in Groningen, The Netherlands and Montreal, Canada. For more information about Kiadis Pharma, please visit '/>"/>

SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Mirus Bio Awarded Grants & Contracts of Over $5 Million
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. NIH grants $750,000 to develop device to determine temperature of neonates brain
5. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
6. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
7. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
10. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
11. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... (PRWEB) August 20, 2014 Not long ... E&L studies should be performed late in the development ... known. But current regulatory trends suggest that, like many ... the rise. In recent years, multiple drug sponsors have ... or address specific questions during phase I/II. It’s not ...
(Date:8/20/2014)... Aug. 20, 2014 /PRNewswire-iReach/ -- A case study ... between the school,s bioengineering department and the Intel® ... Intel® Software Academic Program, UCSD,s research focuses on ... human body.  Photo - ... the work of Dr. Todd P. Coleman ...
(Date:8/20/2014)... improve the health of your heart, researchers have discovered. ... a standard TENS machine like those designed to relieve ... the small raised flap at the front of the ... The stimulation changed the influence of the nervous system ... can drive failing hearts too hard. , Professor Jim ...
(Date:8/20/2014)... WriteResult®, a leading provider of Electronic Patient ... its myPROpad™ ePRO tablet with the addition of a ... most widely used and well-respected Patient Reported Outcome (PRO) ... is used during clinical trials and in other health ... used to demonstrate Health-Related Quality of Life outcomes (HRQoL) ...
Breaking Biology Technology:Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2'Tickling' your ear could be good for your heart 2EQ-5D™ Assessment Now Available for iPad 2
... Call Tomorrow (Tuesday) at 8:30 am EDT to ... Discuss the Clinical ... (NASDAQ: XTLB ; LSE: XTL; TASE: XTL) today announced,the initiation ... norepinephrine reuptake inhibitor (SNRI) - for the treatment of,diabetic neuropathic pain. ...
... CeloNova BioSciences, Inc.,("CeloNova"), a leading developer of ... fully color-coded line of embolic particles,Embozene(TM) Color-Advanced ... and Interventional Radiology Society of Europe (CIRSE) ... ) Embolic microspheres are used to ...
... 7 Monogram,Biosciences, Inc. (Nasdaq: MGRM ) announced ... to present a corporate overview at the,ThinkEquity Partners, G5: ... p.m. Eastern Time (10:30 a.m. Pacific Time) at the ... the live audio broadcast or the subsequent archived,recording, log ...
Cached Biology Technology:XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 2XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 3XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 4XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 5XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 6XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 7CeloNova BioSciences Announces World's First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres 2Monogram Biosciences to Present at the ThinkEquity Partners' Fifth Annual Growth Conference 2
(Date:8/19/2014)... ) -- Scientists at the Houston Methodist Research Institute ... single cells using a pipette -- a common laboratory ... feat and preliminary test results in a recent issue ... . , "Studying single cells and their unique functions ... nanomedicine department. faculty member Lidong Qin, Ph.D., the project,s ...
(Date:8/19/2014)... and other science courses are increasingly being asked ... they have a new textbook to help them ... this month by Princeton Press and co-authored by ... Biological Synthesis (NIMBioS), teaches readers about basic mathematical ... explore and explain biological phenomena. , Suitable for ...
(Date:8/19/2014)... Anyone who has ever had a glass of fizzy ... the air. But in a finding with wide industrial ... push some particles down into the liquid as well. ... aerosol droplets, so we were surprised, and fascinated, to ... the same process injected tiny oil droplets into the ...
Breaking Biology News(10 mins):Moving single cells around -- accurately and cheaply 2New textbook introduces undergraduates to mathematics for the life sciences 2Bubbling down: Discovery suggests surprising uses for common bubbles 2Bubbling down: Discovery suggests surprising uses for common bubbles 3
... ( Lepilemur sahamalazensis ), other than the fact it roosts ... holes, and therefore risks falling victim to predators from both ... kept in any zoo. Prior to this research virtually ... that it has been classified as Critically Endangered, the top ...
... study published today in the journal Gondwana Research ... Antarctic and Indian tectonic plates, demonstrating how they formed ... from Royal Holloway University, The Australian National University and ... how the plates evolved and where they should be ...
... years, pilots flying into combat have jammed enemy radar to ... moths can do it, too. A new study co-authored ... pulses from their genitals to respond to bats producing the ... echolocation ability of their predators. Echolocation research may ...
Cached Biology News:Solitary lemurs avoid danger with a little help from the neighbors 2UF researcher shows hawkmoths use ultrasound to combat bats 2UF researcher shows hawkmoths use ultrasound to combat bats 3
... tissue panels are designed for studying ... or proteins of interest in different ... positively charged glass slides. Total RNA ... identical format, and cDNA from those ...
Total Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
Total Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
... The T2-02 diaphragm pump features T ... and achieves remarkable performance and efficiency. With ... performance range, T2-02 is ideal for use ... Offers ultra-compact size, long life, and high ...
Biology Products: